Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Ferroptosis Modulator Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GSS drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GSS Recombinant Protein (Wild-Type & Mutants) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for enzymatic assays and TSA. |
View GSS Products |
| Gene Delivery | GSS Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View GSS Products |
| Benchmark Ab | Anti-GSS Recombinant Antibody High-affinity positive control for Western Blot, ELISA, and IHC. |
View GSS Products |
| Validator | GSS siRNA Set For target knockdown verification and specificity profiling in cell-based assays. |
View GSS Products |
| Related Target A | GCLC (Glutamate-Cysteine Ligase Catalytic Subunit) The rate-limiting enzyme upstream of GSS in the glutathione synthesis pathway. |
View GCLC Products |
| Related Target B | GPX4 (Glutathione Peroxidase 4) The downstream master regulator of ferroptosis utilizing GSH as a cofactor. |
View GPX4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic activity validation & high-throughput screening | Sequence verified, E. coli or HEK293 expressed recombinant GSS with theoretical MW matching native conformation. |
| Selectivity screening against upstream synthesis enzymes | Homolog and pathway panels (GCLC, GCLM, GPX4) strictly verified by mass spectrometry to eliminate off-target false positives. |
| Lack of reliable positive controls | Sequence-verified clinical benchmark antibodies and high-potency siRNA knockdown pools included. |
| Assay interference from endotoxins | Endotoxin-controlled production process (<1.0 EU/μg) protecting delicate enzymatic and cell-based reporter systems. |
Live GSS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GSS therapeutics is intensifying, with major players shifting focus from traditional metabolic inhibitors to targeted ferroptosis-inducing agents. As first-generation therapies targeting the broader glutathione pathway reach the clinic, the next wave of R&D is targeting GSS directly to selectively deplete glutathione in chemoresistant solid tumors without causing systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic institutions, Oncology biotechs | Solid Tumors, Chemoresistant Cancers, Ovarian Cancer | Enzymatic Activity & Thermal Shift Assays (Need high-purity recombinant GSS) |
| RNAi / siRNA | Preclinical therapeutics developers | Hepatic Malignancies, Metabolic Disorders | Knockdown Validation (Need GSS siRNA and Lentivirus for stable lines) |
| Combination Therapies (with GPX4/xCT inhibitors) | Translational oncology consortia | Ferroptosis-sensitive tumors, Triple-Negative Breast Cancer (TNBC) | Pathway Cross-Screening (Need GCLC, GPX4, and GSS protein panel) |